- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03677544
Predictive Factorsfor Final Pathologic Ureteral Sections (CYSTECTOMEN)
May 16, 2023 updated by: Centre Hospitalier Universitaire, Amiens
Predictive Factorsfor Final Pathologic Ureteral Sections on 700 Radical Cystectomy Specimens: Implicationsforintraoperativefrozensection Decision-making
To identify preoperative predictive factors for final ureteral section invasion after radical cystotomie (RC) and to validate significant factors on an external independent cohort.
The investigators retrospectively reviewed data of all consecutive RC performed for bladder cancer in 2 high-volume institutions.
Clinical, pathological, and follow-up data were collected prospectively and reviewed retrospectively.
Pathological evaluation was performed by 2 well-trained uropathologists in each center.
Logistic regression analyses were performed to identify predictive factors for final ureteral sections involvement.
Significant factors in cohort A were validated in cohort B. Receiver operating curve and area under curve were modeled to evaluate predictive accuracy of the markers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To identify preoperative predictive factors for final ureteral section invasion after radical cystotomie (RC) and to validate significant factors on an external independent cohort.
Pathological evaluation was performed by 2 well-trained uropathologists in each center (Y.A. and C.C).
The investigators retrospectively reviewed data of all consecutive RC performed for bladder cancer in 2 high-volume institutions.
Clinical, pathological, and follow-up data were collected prospectively and reviewed retrospectively.
Pathological evaluation was performed by 2 well-trained uropathologists in each center.
Logistic regression analyses were performed to identify predictive factors for final ureteral sections involvement.
Significant factors in cohort A were validated in cohort B. Receiver operating curve and area under curve were modeled to evaluate predictive accuracy of the markers
Study Type
Observational
Enrollment (Actual)
748
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
In cohort A, most patients did not have intraoperative FS examination although it was performed in some cases depending on the surgeon's habits (N¼92).
All patients had intraoperative FS in the validation cohort B. All cystectomies performed for nononcological purposes were excluded.
All patients had nonmetastatic bladder cancer on preoperative computed tomography (CT) scans.
Description
Inclusion Criteria:
- patients > 18 years
- patients reoperative predictive factors for final ureteral section invasion after radical cystectomy
Exclusion Criteria:
- patients < 18 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
no intraoperative FS examination
Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation.
procedures were performed between 1980 and 2013
|
Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
|
|
intraoperative FS examination
Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
|
Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
preoperative predictive factors
Time Frame: 2years
|
The objective of this study is to identify preoperative predictive factors for final ureteral section invasion after radical cystectomy (RC) and to validate significant factors on an external independent cohort.
|
2years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Fabien Saint, MD, PhD, CHU Amiens
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
September 18, 2018
First Submitted That Met QC Criteria
September 18, 2018
First Posted (Actual)
September 19, 2018
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
May 16, 2023
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI2017_843_0051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncTerminatedMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Vadim S KoshkinImmunityBio, Inc.WithdrawnUrothelial Carcinoma | Urothelial Cancer | Metastatic Urothelial Carcinoma | Locally Advanced Urothelial CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)RecruitingStage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma | Muscle Invasive Renal Pelvis Urothelial Carcinoma | Muscle Invasive Ureter Urothelial... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
Sun Yat-sen UniversityTongji Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The... and other collaboratorsRecruitingUrothelial Carcinoma | Urothelial Carcinoma Recurrent | Advanced Urothelial CarcinomaChina
Clinical Trials on laparoscopic approach with an extended pelvic lymph
-
University of Turin, ItalyAIRC (Italian Association for Cancer Research); Fondazione Ricerca MolinetteRecruiting
-
University Hospital, Basel, SwitzerlandRecruitingProstate Cancers | Prostate Cancer SurgerySwitzerland
-
Zagazig UniversityCompleted
-
Oslo University HospitalUniversity Hospital, AkershusRecruiting
-
RenJi HospitalUnknown
-
Yonsei UniversityRecruitingGastric CancerKorea, Republic of
-
Istituto Clinico HumanitasActive, not recruitingLymph Node Cancer MetastaticItaly
-
University of AarhusOdense University Hospital; Rigshospitalet, Denmark; Herlev Hospital; Vejle Hospital and other collaboratorsCompleted
-
N.N. Alexandrov National Cancer CentreRecruitingProstate Cancer Patients Undergoing Radical ProstatectomyBelarus
-
Shuguo Zheng, MDUnknownLiver Diseases | Liver Neoplasms | Hepatic HaemangiomaChina